Key HighlightsNetRevenuewas about USD 635,000 in the third quarter of 2026, up 247% from about USD 183,000 a year earlier, asDemandgrew for QUELIMMUNE, its therapy for ultra-rare pediatric kidney injury.Net loss was about USD 4.5 million, or USD 1.03 per share, against about USD …
Risto-cel uses base editing, which changes single DNA letters without cutting both strands of the genome. The goal is to switch on fetal haemoglobin, which protects red blood cells from sickling. Two gene therapies for sickle cell disease are already approved, so Beam is …
The company held USD 193.3 million in cash, cash equivalents and marketable securities, against an accumulatedDeficitof USD 199.1 million. In July 2026 it sold 25,000,000 shares to RA Capital Management through its at-the-marketFacilityfor gross proceeds of USD 50.0 million, and 18,030,000 of those shares …
The chief financial officer said cash burn was USD 7.1 million in the quarter, or about USD 2.4 million a month, up from USD 6.4 million in the second quarter, and that burn should rise as spending on the two Department of Energy pilot …
Caplyta came to the company through its 2025Acquisitionof Intra-Cellular Therapies, and it is already approved for bipolar I and II depression and for major depressive disorder as an add-on or stand-alone therapy, as well as for schizophrenia. Adding mania would let the drug cover …
Total operating expenses eased to USD 3.65 million from USD 3.71 million, with selling, general and administrative costs of USD 2.58 million offset by higher development and regulatory spending of USD 829,544. Loss from operations narrowed to USD 2.68 million. Net cash used inOperating …
The third-quarter net loss was USD 21.0 million, compared with USD 20.1 million a year earlier.Research and Developmentspending fell to USD 16.1 million from USD 18.1 million as trial enrolment wound down, while general and administrative costs rose to USD 12.7 million from USD …
Dazodalibep came to Amgen with itsAcquisitionof Horizon Therapeutics, a deal built on the promise of rare and autoimmune disease medicines. Sjogren's disease affects millions of people worldwide, many of them women, and a therapy that modifies the disease could become a large product if …
The net loss narrowed to USD 2.6 million, or USD 0.50 per share, with general and administrative expense down 44% to USD 1.0 million. Research and development rose to USD 1.8 million on the randomized Phase 2 study and translational work. Cash of USD …
The company expects to start its rolling submission by the end of 2026, complete it in the first half of 2027 and potentially win approval in 2027. A non-viral approach is simpler to manufacture than viral gene therapies and can be given in a …